Rhythm Pharmaceuticals (RYTM) Operating Leases (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Operating Leases data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 17.61% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 17.61% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 15.13% from the prior year.
• Operating Leases for Q1 2026 stood at $3.2 million, down from $3.3 million in the prior quarter.
• Over the last five years, Operating Leases for RYTM reached as high as $4.0 million in Q3 2024 and fell as low as $284000.0 in Q1 2024.
• Historically, Operating Leases has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
• Across the five-year window, Operating Leases slumped 73.61% in 2024 and jumped 1251.76% in 2025, its largest moves.
• Year by year, Operating Leases stood at $1.3 million in 2022, then sank by 61.11% to $490000.0 in 2023, then soared by 703.67% to $3.9 million in 2024, then fell by 15.13% to $3.3 million in 2025, then retreated by 5.36% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $3.2 million in Q1 2026, $3.3 million in Q4 2025, and $3.5 million in Q3 2025.